Home / Business and Economy / Novo Nordisk Sues Hims & Hers Over Unapproved Weight Drugs
Novo Nordisk Sues Hims & Hers Over Unapproved Weight Drugs
9 Feb
Summary
- Novo Nordisk alleges Hims & Hers sold unapproved weight-loss drugs.
- High impurity levels found in Hims' compounded semaglutide products.
- Regulators warn against unapproved GLP-1 drugs due to safety concerns.
US drugmaker Novo Nordisk has initiated legal action against telehealth company Hims & Hers, alleging the illegal sale of unapproved weight-loss and diabetes medications. The lawsuit centers on compounded semaglutide products, which Novo Nordisk claims infringe on its patents and bypass FDA approval processes.
Novo Nordisk asserts that Hims & Hers is marketing these "knock-off" versions as safe and effective alternatives, despite lacking regulatory clearance. Testing by Novo Nordisk reportedly found significant impurity levels, raising concerns about patient safety, including potential immune reactions and overdoses.
Both the FDA and major medical associations have cautioned against the use of unapproved compounded GLP-1 drugs, citing uncertainties in their quality, safety, and efficacy. This legal battle highlights growing tensions in the lucrative weight-loss drug market between established pharmaceutical firms and emerging telehealth providers.
